PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administrationa (FDA), Silver Spring, Maryland, USA.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1093/cid/ciab317
?:doi
?:hasPublicationType
?:journal
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
is ?:pmid of
?:pmid
?:pmid
  • 33861337
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Impact of Convalescent Plasma Therapy on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Profile in Coronavirus Disease 2019 (COVID-19) Patients.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all